ten Hoeve J, Kaartinen V, Fioretos T, Haataja L, Voncken J W, Heisterkamp N, Groffen J
Department of Pathology, Childrens Hospital of Los Angles, California 90027.
Cancer Res. 1994 May 15;54(10):2563-7.
Chronic myelogenous leukemia is characterized by a specific chromosomal translocation, t(9;22), in which the ABL protooncogene and the BCR gene become juxtaposed. The chimeric BCR/ABL gene produces a P210 fusion protein with deregulated tyrosine kinase activity. We have recently isolated a complementary DNA, CRKL, which could code for an adaptor protein consisting of one SH2 and two SH3 domains and lacking any catalytic domain. In the current study, we show that CRKL is highly phosphorylated in the chronic myelogenous leukemia cell line K562 and that it is a substrate for the p210 BCR/ABL and p145 ABL kinases. BCR/ABL and ABL are coimmunoprecipitated with CRKL in vivo, demonstrating that relatively stable complexes are formed. In addition, the nucleotide exchange factor mSOS1 was found to be coimmunoprecipitated with CRKL. These findings establish a putative signal transduction pathway way through which BCR/ABL mediates its oncogenic activity.
慢性粒细胞白血病的特征是特定的染色体易位,即t(9;22),其中ABL原癌基因和BCR基因并列。嵌合的BCR/ABL基因产生具有失调酪氨酸激酶活性的P210融合蛋白。我们最近分离出一种互补DNA,即CRKL,它可以编码一种由一个SH2和两个SH3结构域组成且缺乏任何催化结构域的衔接蛋白。在当前研究中,我们表明CRKL在慢性粒细胞白血病细胞系K562中高度磷酸化,并且它是p210 BCR/ABL和p145 ABL激酶的底物。BCR/ABL和ABL在体内与CRKL共同免疫沉淀,表明形成了相对稳定的复合物。此外,发现核苷酸交换因子mSOS1与CRKL共同免疫沉淀。这些发现建立了一条假定的信号转导途径,通过该途径BCR/ABL介导其致癌活性。